The Department of Health and Human Services today announced an agreement with drug maker Gilead Sciences to allow U.S. hospitals to purchase up to 500,000 treatment courses of remdesivir through September, which HHS and state health departments will allocate as they did the previous 120,000 treatment courses donated by the drug maker.

Under the agreement, hospitals will pay no more than the wholesale acquisition price for the drug, or $3,200 per treatment course, which AmerisourceBergen likely will ship to them every two weeks. The investigational drug has shown encouraging results treating certain COVID-19 patients in early clinical trials. HHS said the final donated treatment courses will ship today. To make future allocations of remdesivir, HHS will be asking hospitals and health systems to submit data every two weeks. The next data collection will be July 6.

AHA members will receive a Special Bulletin with more details.

Related News Articles

Headline
A new AHA podcast explores how rural hospitals have found new ways to deliver care to patients with COVID-19. Brian Evans, CEO of Clarke County Hospital in…
Headline
Certain groups of workers showed significantly more absenteeism in March and April 2020, suggesting a link to COVID-19 exposure, according to a new study…
Headline
The Department of Health and Human Services today announced that it will distribute over $4 billion in additional funds from the Public Health and Social…
Perspective
Wear a mask. Wash your hands. Keep your distance. These are three simple actions we know that will stop the spread of COVID-19. The AHA, American Medical…
Headline
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune…
Headline
Gilead Sciences yesterday said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement,…